OBJECTIVES: Although percutaneous edge-to-edge mitral valve repair with the MitraClip system is becoming widely adopted in clinical practice, surgical experience on how to correct failed MitraClip therapy is limited. We aimed to analyse the surgical and pathological outcomes after surgical revision of the failed MitraClip therapy.
INTRODUCTION
Percutaneous edge-to-edge mitral valve repair with the MitraClip system (Abbott Vascular, Santa Clara, CA, USA) is becoming widely adopted in clinical practice due to its reported safety in elderly and other high-risk patients, providing an acute success rate of 92% [1] , acceptable in-hospital mortality of 2.5-2.7% [2] [3] [4] [5] and acceptable 1-year survival free from cardiac depression of 14-23% [6] [7] [8] . Meanwhile, 2.3-6.3% of patients require surgical repair and mitral valve replacement (MVR) due to various complications within 1 year after MitraClip therapy [6] . As few studies have described the outcomes of patients with surgical revision after failed MitraClip implantation [9, 10] , the optimal surgical strategy for open-heart operations after failed MitraClip therapy is not well defined. In this study, we evaluated the postoperative clinical outcomes and intraoperative pathological findings of patients who underwent surgical revision for failed MitraClip therapy. We believe that this analysis will contribute immensely to future practice involving the MitraClip system and to the development of a suitable surgical strategy for open-heart operations after failed MitraClip therapy.
MATERIALS AND METHODS

Study design
With approval from the Institutional Review Board of the Sana Heart Center, we retrospectively reviewed the records of consecutive patients who, between January 2011 and January 2018, underwent MVR for recurrent or uncontrolled mitral regurgitation (MR) despite adequate medical therapy after percutaneous MitraClip therapy. Clinical data were collected. Information about the follow-up status was obtained by phone and fax from the treating general physician or from the patients themselves.
The study end points were death and cardiac-related death.
A heart team consisting of a cardiologist, cardiac surgeon, perfusionist and cardioanaesthesiologist discussed the surgical revision. All patients provided written informed consent for undergoing the revision operation.
Surgical procedures
MVR was performed to reduce the duration of aortic crossclamping and cardiopulmonary bypass. All procedures were performed via the median sternotomy or right thoracotomy approach, at the discretion of the surgical team. Full sternotomy was chosen for critically ill patients and for those undergoing redo surgery. After sternotomy, cardiopulmonary bypass was established through direct cannulation of the ascending aorta and right atrium vein (20 patients, 80%). Following right anterolateral thoracotomy at the fourth intercostal space, cardiopulmonary bypass was established through cannulation of the femoral artery and vein (5 patients, 20%). After transthoracic aortic cross-clamping, myocardial arrest was obtained with antegrade warm blood cardioplegia (18 patients, 72%) or Bretschneider cardioplegia (7 patients, 28%). The mitral valve was exposed via the standard left atriotomy or the transseptal approach, depending on the need for tricuspid valve repair and atrial septal defect closure. The failure characteristics of the implanted clips and the degree of tissue damage to the mitral valve were assessed. The clips were cut using scissors and removed, and standard MVR was performed.
Follow-up
We evaluated data collected at 48 h, 30 days, 6 months and up to 5 years postoperatively. Follow-up data were complete in all patients.
Statistical analysis
Data are expressed as mean ± standard deviation or median [range and/or interquartile range (IQR)] for continuous variables, and as frequency (%) for categorical variables. Univariable comparisons were performed using the Student's unpaired t-test for continuous, normally distributed data, the Mann-Whitney U-test for non-parametric continuous data and the Fisher's exact test for categorical data. The Kaplan-Meier analysis was used to compute 1-year survival. The statistical significance was set at a P-value <0.05. All reported P-values are 2-sided. The statistical analysis was performed by a statistician using SPSS for Windows, version 22.0 (IBM Japan, Tokyo, Japan).
RESULTS
Study population
Between January 2011 and January 2018, 25 patients (age 73 ± 9 years; age range 52-85 years; men 48%) underwent MVR for severe MR at a median of 54 days (range 1-1496 days) after MitraClip edge-to-edge repair. During the study period, MVR was conducted in 8 (3.21%) of 249 patients who underwent the original intervention at our hospital and in 17 patients who underwent the original intervention at another hospital. Among the 8 patients originally treated at our hospital, the average MR grade after the MitraClip procedure was 2.
Preoperative characteristics
The preoperative New York Heart Association (NYHA) functional class was III or IV (mean 3.4 ± 0.49) in all patients. An average of 2.2 ± 0.93 clips had been implanted per patient (IQR 1.5-3; range 1-4). Disease aetiology at the time of MitraClip implant included primarily functional MR (n = 22, 88%), followed by degenerative MR (n = 2, 8%) and combined degenerative and functional MR (n = 1, 4% 
Operative data
Most patients (24/25, 96%) received a biological valve, whereas 1 patient (4%) received a mechanical valve. The duration of cardiopulmonary bypass and aortic cross-clamping was 117 ± 57 and 61 ± 24 min, respectively. Concomitant procedures included tricuspid valve repair in 7 patients, aortic valve replacement in 2 patients, coronary artery bypass grafting in 1 patient and cryoablation of atrial fibrillation in 4 patients. In 11 patients, the artificial atrial septal defect created due to the transseptal approach for the MitraClip therapy was closed with a suture from the right atrium side. According to the guidelines, 2 patients received an intra-aortic balloon pump and 2 received extracorporeal membrane oxygenation. Nitric oxide gas was used in 1 patient (Table 2) .
Early clinical outcomes
One patient died during surgery because of severe low cardiac output. There were 7 in-hospital deaths (28%), all among patients at very high surgical risk (logistic EuroSCORE: median 58.8%; IQR 34.6-92.3%; range 21.2-96.6%) ( Table 2 ). In 6 of 7 cases, death occurred mainly because of the pre-existing cardiogenic shock or septic shock within 30 days after surgery. Among the 8 patients undergoing urgent surgery, 1 with logistic EuroSCORE 56.9% died due to multiorgan failure (MOF) within 48 h postoperatively despite intraoperative implantation of extracorporeal membrane oxygenation. Among the 3 patients undergoing emergent surgery, 2 patients died because of MOF caused by systemic inflammatory response syndrome resulting in septic shock, renal failure or liver failure. All 3 patients with liver complications died because of MOF within 48 h after surgery. One patient received a left ventricular assist device at 3 days postoperatively but died because of sepsis and MOF at 33 days postoperatively. Among the 18 survivors, 2 required re-exploration for bleeding, 1 required reintubation for pulmonary pneumonia and 1 developed new atrioventricular block requiring pacemaker implantation. Two patients were transferred to the neurology department due to a transient cerebrovascular event. All other patients were discharged to rehabilitation homes or home at a median of 12.5 days (IQR 8.8-28.8; range 1-80 days), with no residual MR or endocarditis noted on thoracic echocardiography at discharge.
Variables related to in-hospital survival
There was a significant association with in-hospital survival for several preoperative variables including logistic EuroSCORE at surgery, left ventricular ejection fraction and liver dysfunction. No such association was noted for age, sex, acute or chronic renal failure, MR grade, cardiogenic shock, NYHA functional class, operative situation (emergent versus urgent versus elective) and time between MitraClip therapy and revision cardiac surgery (Table 3) . 
Late clinical outcomes and survival
The median follow-up was 13 months (IQR 7-32; range 2-76 months). During follow-up, 8 patients died. One patient died after 10 months due to bladder cancer, whereas another patient died of sepsis within 6 months after surgery. The cause of death was unknown in 6 patients. On Kaplan-Meier overall survival analysis, the 6-month, 1-and 2-year survival rates were 68%, 53% and 47%, respectively. There was no stroke, prosthesis dysfunction or endocarditis. No patients received redo surgery.
Intraoperative pathological and microbiological findings associated with the MitraClip system
Recurrent MR was caused by mitral valve leaflet damage due to tear (n = 10), degeneration (n = 3) or infection (n = 3) associated with the MitraClip system and by uncontrolled mitral annulus dilation (n = 7) (Fig. 1, Table 2 ). Although complete detachment of the clip did not occur, partial detachment (defined as detachment of the clip from a single leaflet) occurred in 6 of 10 patients with mitral leaflet tear. In 5 patients (83%) with partial detachment, the posterior mitral valve leaflet was torn and the MitraClip had partially migrated onto the anterior mitral valve leaflet. MR due to leaflet tear or clip detachment occurred within 6 months of MitraClip therapy in 9 patients (90%) and later in 1 patient (10%) (Fig. 2) . In 3 patients, vegetation was noted near the MitraClip (Table 2 ). Blood cultures were positive for Staphylococcus aureus (acute phase), Enterococcus faecalis (chronic phase) and Staphylococcus epidermidis (subacute phase), respectively. In 2 patients, the infection-related tissue damage had led to tears in the mitral valve leaflet. These patients did not have chordae rupture, and the infection did not reach the mitral annulus or the other valves.
Mitral valve degeneration included myxomatous and endothelialization changes around the MitraClip implantation areas (fibrous encapsulation of the clip, with extension over adjacent mitral leaflets and tissue bridge formation), which were noted in 3 patients at 2, 17 and 49 months, respectively. Perioperative mortality was not influenced by the time interval between MitraClip therapy and revision surgery or by pathological findings noted intraoperatively (Table 3) .
DISCUSSION
Overview of findings
In the past 7 years, 25 patients including those with sepsis and cardiogenic shock state received the bail-out therapy for patients at our centre for recurrent severe MR after MitraClip therapy. In this series, the 30-day mortality was 24%, which we consider acceptable in a population with high surgical risk. Geidel et al. [10] reported a 30-day mortality of 9.1% in a case series that did not include patients presenting with sepsis or undergoing cardiopulmonary resuscitation. The most important findings of this study were as follows: (i) surgical revision after failed MitraClip therapy is a feasible option even in high-risk patients; (ii) patients presenting with liver failure, cardiogenic shock or septic shock are at extremely high risk for in-hospital mortality; and (iii) the predominant pathology underlying MR after failed MitraClip therapy is mostly related to mitral valve leaflet damage due to tear, degeneration or infection associated with the clip itself.
Survival predictors
Variables predicting postoperative survival (in particular, inhospital survival) are used for risk stratification and represent important factors in the decision to perform surgery. In the present series, 6 patients (24%) died within the first 48 h due to MOF. All non-survivors had a logistic EuroSCORE >35% plus one or more risk factors including shock of either aetiology, age >80 years or severe left ventricular dysfunction. Elhmidi et al. [11] also suggested that the combination of preoperative cardiogenic shock with severe left ventricular dysfunction represents a high risk for in-hospital death. A recent study reported that the conservative therapy is advisable in patients with logistic EuroSCORE >30% [10] . In our present series, the average logistic EuroSCORE at the time of surgery was 62% among patients who died before discharge; however, 8 patients (44%) who survived until discharge also had a logistic EuroSCORE >30% at surgery. In addition, all patients with severe liver dysfunction died within 48 h after surgery. In 2 such patients, liver failure occurred due to shock. Of the patients requiring mechanical support with extracorporeal membrane oxygenation or intra-aortic balloon pump implantation, none survived (survivor versus non-survivor, P < 0.0001). Taken together, our findings suggest that the decision to perform surgery should take into consideration not only the value of the logistic EuroSCORE but also other factors reflecting MOF (in particular, liver failure).
Leaflet tears
Leaflet tears typically occurred within 6 months after MitraClip therapy. Clip detachment likely occurred due to substantial tension in the repaired leaflet, causing leaflet tear secondary to progressive mitral annulus dilation or valve disruption due to hypertension or atrial fibrillation. In 1 patient, leaflet tear occurred later than 6 months after MitraClip therapy and echocardiography revealed mild mitral stenosis. Partial clip detachment may have been caused by pressure overload of the MitraClipimplanted valve in the chronic phase. Therefore, mild mitral valve stenosis during follow-up after MitraClip therapy represents a very important clinical finding.
In all cases, partial detachment was caused by posterior leaflet tears. In functional MR due to left atrial dilation and mitral annulus dilation, the posterior wall of the left atrium expands posteriorly, whereas the posterior wall of the left ventricle bends anteriorly, causing the posterior leaflet to bend and expand according to the movement of the posterior wall of the left ventricle. The anterior leaflet flattens out during valve opening. Thus, as posterior leaflets that shift posteriorly tend to be shorter, MitraClip therapy increases the risk of tear at this location.
Leaflet infection
In this study, infective endocarditis was found in 3 patients (mean MR grade 3), of whom 2 had clip-related leaflet tear. Infective endocarditis with S. aureus occurred in the acute phase (12 days) after MitraClip therapy in a patient with severe progressive MR (EuroSCORE II, 81.6%) who underwent emergent MVR but died due to septic shock. Meanwhile, infective endocarditis with S. epidermidis and E. faecalis, respectively, occurred in the subacute (13 months) and chronic phase (49 months) after clip implantation and these patients had progressive MR (EuroSCORE II: 6.2% and 21.1%, respectively) but survived.
Prosthetic valve endocarditis, mostly due to S. aureus infection, has been reported for up to 30% of all patients with infective endocarditis [12] . However, the incidence of MitraClip-related endocarditis is unknown. Frerker et al. [13] were the first to report a case of S. aureus-related endocarditis after MitraClip therapy. In our hospital, none of the other 250 patients implanted with MitraClips developed endocarditis over a follow-up of 5 years, suggesting that infective endocarditis in MitraClip-implanted patients is extremely rare. However, patients with severe circulatory compromise preoperatively have extremely high risk of postoperative mortality, especially if the causal agent is S. aureus. MitraClip implantation may increase the risk of infective endocarditis because residual MR is common after MitraClip therapy and the clip itself is a foreign object that can serve as a suitable habitat for bacteria. Therefore, although the risk of prosthetic valve endocarditis is low, the patients should be carefully monitored for signs of infective endocarditis in both the acute and late phase after MitraClip therapy.
A recent review reported a 42% rate of postoperative mortality associated with MitraClip-related infection, with S. aureus as the most frequent (60%) causal micro-organism [14] . We believe that acute infective endocarditis with S. aureus, and the subacute or chronic infective endocarditis may follow acute haemodynamic alteration due to tear or deterioration of the mitral valve. The rate of infective endocarditis following MitraClip therapy appears to be lower than that associated with the implantation of mechanic or bioprosthetic valves.
Leaflet degeneration
In our series, 3 patients (12%) had degenerative changes in the leaflet region around the MitraClip. The healing response to the MitraClip device in humans is currently not well understood.
According to Stephens et al. [15] , regurgitation alone can result in leaflet remodelling characterized by increased matrix degeneration, collagen synthesis and abundance of elastin in the spongiosa and fibrosa layers following mitral valve deterioration. We hypothesize that the MitraClip system may trigger aggressive inflammatory reactions leading to formation of fibrotic tissue around the implanted clip, which sometimes results in mitral stenosis.
Interestingly, 2 of 3 patients with MitraClip-related degeneration had mediastinal radiation therapy due to mammary carcinoma before MitraClip therapy. Cardiac valve disease associated with mediastinal radiation therapy is characterized by valve fibrosis and calcification, often with progression to heart failure and death. Our 2 patients presented obvious mitral leaflet degeneration at 1454 and 503 days after MitraClip therapy, respectively. The MitraClip itself may have stimulated the progress of degeneration caused by mediastinal radiation therapy. In another patient, progressive endothelialization around the MitraClip was noted at 54 days after MitraClip therapy. The reason for this acute healing reaction around the clip is unknown. Although the pathology associated with leaflet remodelling appeared to differ according to the time after the MitraClip procedure, the type of pathological findings had no significant influence on perioperative mortality (Table 3) . Further studies are warranted to clarify the characteristics and clinical relevance of leaflet remodelling in response to MitraClip implantation in humans.
Limitations
The baseline characteristics in this case series were heterogeneous, the sample size was small, and our experience relates only to a single institution. Moreover, 60% of patients were transferred from other interventional hospitals, suggesting that not all patients with failed MitraClip therapy may have been referred for surgical revision. Therefore, selection bias could not be excluded. Multicentre studies with large sample size and long follow-up are required to confirm the mitral valve alterations associated with the MitraClip therapy. 
CONCLUSION
Open-heart surgery after unsuccessful MitraClip treatment is acceptable at any time in patients with high surgical risk. However, it may be too late to operate in patients with established MOF due to shock. Based on our experience of 7 years, we recommend the following: (i) MitraClip-implanted patients should be regularly followed-up by a heart team to monitor for MitraClipassociated infection or degenerative alterations of mitral valve leaflets, even if no partial detachment is noted in the early phase; and (ii) patients with recurrent MR after MitraClip therapy should be operated before MOF establishment, with shock-induced liver failure carrying a very high risk of perioperative mortality.
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